



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314101036)

Date: 13th November, 2025

To,
The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400001.

Sub : Submission of Unaudited Financial Results for the quarter and half year ended 30th September, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref : Scrip Code: 536565

Scrip Id: NOVELIX

Respected Sir/Madam,

Pursuant to the Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), the Board of Directors at their meeting held on 13th November, 2025 have considered and approved, the Unaudited Financial Results of the company for the quarter and half year ended 30th September, 2025 along with the limited review report of the auditors thereon.

A copy of the results along with the limited review report of auditors is enclosed herewith.


The said meeting commenced at 05:00 P.M. and concluded at 05:30 P.M.

Kindly acknowledge the receipt.

Thanking You,
Yours sincerely,

For Novelix Pharmaceuticals Limited

Venka



Venkateshwarlu Pulluru
(Whole-time director)
DIN: 02076871

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



CVS Balachandra Rao & Co.,
Chartered Accountants

Limited Review Report on Standalone Unaudited Quarterly Financial Results of Novelix Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors
Novelix Pharmaceuticals Limited


We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **Novelix Pharmaceuticals Limited** for the quarter ended on 30th September, 2025, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For CVS Balachandra Rao & Co.,
Chartered Accountants
ICAI Firm Regd No: 007507S


CVS Balachandra Rao
Partner
Membership Number: 204580
UDIN: 25204580BMHZZL7022
Date: 13/11/2025
Place: Hyderabad





Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314101036)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2025

Sr. No	Particulars	Rs. (In Lakhs)					
		3 Months ended	Preceding 3 Months ended	Corresponding 3 Months ended in previous year	6 Months ended	Corresponding 6 Months ended in previous year	Year ended
		30/09/2025 Unaudited	30/06/2025 Unaudited	30/09/2024 Unaudited	30/09/2025 Unaudited	30/09/2024 Unaudited	31/03/2025 Audited
1	Revenue						
	a) Income from Operations (Net)	3,635.89	2,235.12	395.66	5,871.01	455.77	3,071.85
	b) Other Income	3.25	0.00	-8.29	3.25	1.49	1.60
	Total income (a + b)	3,639.14	2,235.12	387.37	5,874.26	457.26	3,073.44
2	Expenses						
	a) Cost of material consumed						-
	b) Excise duty	-	-		-	-	-
	(c) Purchase of stock-in-trade	3,668.48	2,249.50	302.93	5,917.98	339.50	2,922.25
	(d) Changes in inventories of finished goods, work-in- progress and stock-in-trade	-149.67	-71.64	45.33	-221.32	87.30	35.12
	(e) Employee benefits expense	14.18	16.46	1.714	30.63	5.35	6.86
	(f) Finance cost	-	-		-		-
	(g) Depreciation and amortization expense	1.38	1.10	0.48	2.48	0.97	3.80
	(h) Other expenses	32.89	22.76	23.84	55.65	45.65	93.08
	Total Expenses	3,567.25	2,218.17	374.30	5,785.42	478.77	3,061.11
3	Profit and (Loss) before exceptional items and tax	71.89	16.95	13.07	88.84	(21.51)	12.33
4	Exceptional Items						
5	Profit and (Loss) after exceptional items but before Tax	71.88	16.95	13.07	88.84	(21.51)	12.33
6	Tax Expenses						
	(a) Current Tax	18.03	3.54	0.00	21.57	0.00	2.96
	(b) Deferred Tax	0.54	2.70	0.12	3.24	0.92	0.92
7	Total Tax Expenses	18.57	6.23	0.12	24.81	0.92	3.88
8	Net Profit/ (Loss) for the Period (5-7)	53.31	10.71	12.95	64.03	(22.44)	8.45

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com





Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

9	Other Comprehensive Income/(Loss)						
	A) (i) Items that will not be reclassified to Profit & Loss						
	(ii) Income tax relating to items that will not be reclassified to profit & loss						
	B) (i) Items that will be reclassified to Profit & Loss						
	(ii) Income tax relating to items that will be reclassified to profit & loss						
10	Total Comprehensive Income/(Loss) (8+9)	52.47	10.71	12.95	64.03	-22.44	8.45
11	Paid up equity share capital (Face Value: Rs. 10 per share)	1,448.00	995.00	995.00	1,448.00	995.00	995.00
12	Earnings per equity share						
	a) Basic	0.37	0.11	0.16	0.44	-0.27	0.08
	b) Diluted	0.49	0.12	0.16	0.59	-0.27	1.09

NOTES:


1	The above Unaudited Financial Results of the company for the quarter ended September 30th 2025 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on 13 November, 2025.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com





Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

	active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website https://novelixpharma.com

By the order of the Board
For Novelix Pharmaceuticals Limited

Venkateshwarlu



Venkateshwarlu Pulluru

(Whole-time director)

DIN: 02076871

Date: 13/11/2025

Place: Hyderabad

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



Novelix Pharmaceuticals limited


(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314101036)

Segment Revenue & Segment Profit:

						Rs. (In Lakhs)
	Pharma Business	Investment in Shares	Trading in shares	Foods	Finance	Total
I. Revenue						
-Sales	5,871.01					5,871.01
-Other Income	3.25	-	-			3.25
	5,874.26					5,874.26
II. Expenditure						
-Purchase	5,917.98			-		5,917.98
-Cost of Material consumed	-	-		-	-	-
-Manufacturing Exp	-	-		-	-	-
-Changes in Inventory	-221.32	-		-		-221.32
-Employee Benefits Expenses	30.63			-		30.63
-Finance Cost						
-Depreciation & Amortization Expense	2.48			-		2.48
-Other Expenses	55.65	-		-		55.65
	5,785.42			-		5,785.42
	-	-	-	-	-	-
Profit/ (Loss)	88.84	-	-	-	-	88.84
Less: Income Tax Paid for Earlier Years						
	-	-	-	-	-	-
	88.84	-	-	-	-	88.84

By the order of the Board
For Novelix Pharmaceuticals Limited

Venkaiah



Venkateshwar Reddy Pulla
(Whole-time director)
DIN: 02076871
Date: 13/11/2025
Place: Hyderabad

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com
www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2025

Rs. (In Lakhs)

PARTICULARS		As at 30th September 2025	As at 31-March 2025
		(Un Audited)	(Audited)
	ASSETS		
1	Non - current assets		
(a)	Property, plant and equipment	41.88	18.57
(b)	Capital work in progress	-	-
(c)	Investment property	-	-
(d)	Intangible assets	70.95	0.00
(e)	Financial assets	-	-
	(i) Investments	4.32	4.32
	(ii) Loans	-	-
	(iii) Other financial assets	-	-
(f)	Deferred tax Assets (Net)	1.22	4.46
(g)	Other Non-current assets	-	-
	Total non-current assets	118.37	27.35
2	Current assets		
(a)	Inventories	305.64	84.32
(b)	Financial assets		
	(i) Investments	-	-
	(ii) Trade receivables	5,672.91	1,813.69
	(iii) Cash and cash equivalents	145.01	67.86
	(iv) Other balances with banks	-	-
	(v) Loans	878.01	702.31
	(vi) Other financial assets	-	-
(c)	Other Current assests	60.39	25.11
	Total current assets	7061.96	2693.29
	TOTAL ASSETS	7180.33	2720.65
	EQUITY AND LIABILITIES		
1	Equity		
(a)	Share capital	1,448.00	995.00
(b)	Other equity	1,112.96	758.93
	Total Equity	2560.96	1753.93
2	Non-current liabilities		
(a)	Financial liabilities	-	-
	(i) Long-term borrowings	-	-
	(ii) Deferred tax liabilities (net)	-	-
	(iii) Other financial liabilities	-	-
(b)	Provisions	-	-
(c)	Other Non Current liabilities	-	-
	Total non-current liabilities	0.00	0.00
3	Current liabilities		
(a)	Financial liabilities	-	-

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com





Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314101036)

	(i) Borrowings	-	-
	(ii) Trade payables	4,549.40	920.11
	(iii) Other financial liabilities	-	-
(b)	Provisions	69.63	36.60
(c)	Other current Liabilities	0.34	10.00
	Total current liabilities	4619.37	966.72
	Total Liabilities	4619.37	966.72
	TOTAL EQUITY AND LIABILITIES	7180.33	2720.65

By the order of the Board
For Novelix Pharmaceuticals Limited



Venkateshwarlu Pulluru

(Whole-time director)

DIN: 02076871

Date: 13/11/2025

Place: Hyderabad

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com



Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314101036)

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30th September 2025

Particulars	Rs. (In Lakhs)	
	As at 30-09-2025	As at 31-03-2025
A. Cash Flow from Operating Activities:		
Net Profit before Tax and Extraordinary Items	64.03	12.33
Adjustments for:	-	-
Depreciation	2.48	3.80
Interest & Other Income	(3.25)	(1.60)
Loss on Sale of Fixed Assets		
Loss on Sale of Investments & Property		
Profit on sale of mutual funds		
Operating profit before Working Capital Changes	63.25	14.54
Adjustments for:		
Trade and Other receivables	3,629.29	(2,259.35)
Inventories	(221.32)	35.12
Trade & Other payables	(4,070.21)	841.24
Other Current Liabilities	(9.66)	-
Short-Term Provisions	36.27	-
Cash generated from Operations	(635.63)	(1,382.99)
Cash flow before Extraordinary Items	(572.38)	(1,368.46)
Extraordinary Items and Tax		
Net Cash used for Operating activities	(572.38)	(1,368.46)
B. Cash Flow from Investing Activities:		
Purchase of Fixed Assets	(96.73)	(10.61)
Sale of Fixed Assets	-	-
Capital Work in progress	-	-
Sale of Investments	-	302.05
Increase / (Decrease) in Security Deposits	-	-
Interest & Other Income	3.25	1.60
Net Cash flow from Investing activities	(93.48)	293.04
C. Cash Flow from Financing Activities:		
Increase in Share Capital	453.00	185.00
Increase in Share Premium	453.00	121.50
Increase / Decrease in Long Term Borrowings	-	-
Share Issue and Preliminary Expenses	-	-

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com






Novelix Pharmaceuticals limited

(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Warrents Issued	(163.00)	825.00
Net Cash flow from Financing activities	743.00	1,131.50
Net Increase in Cash and Cash Equivalents (A+B+C)	77.14	56.08
Cash and Cash Equivalents as at (Opening Balance)	67.86	11.78
Cash and Cash Equivalents as at (Closing Balance)	145.01	67.86

By the order of the Board
For Novelix Pharmaceuticals Limited



Venkateshwarlu Pulluru
(Whole-time director)
DIN: 02076871
Date: 13/11/2025
Place: Hyderabad

Novelix Pharmaceuticals limited

(Formerly Known as TRIMURTHI LIMITED)

H No: 3-6-237/610, Flat No: 610, 6th Floor, Lingapur LA Builders, Also Known as Amrutha Estates, Himayat Nagar, Hyderabad, Telangana- 500029 Ph No: +91 8977631044 Email: novelixpharmaceuticals@gmail.com

www.novelixpharma.com